NCT02044549

CompletedPhase 4

Carbetocin Versus Syntometrine for Prevention of Postpartum ...

Cairo University Source

Compare

Other study identifiers

Sponsor study identifier

Carbitocin

Study Type

interventional

Actual enrollment (reported)

300

Locations

1 country

Sites

1

Timeline

Study Start

June 2014

Actual (reported)

Primary Completion

December 2015

Actual (reported)

Study Completion

December 2015

Actual (reported)

Brief Summary

to compare effectiveness and tolerability of carbetocin versus syntometrine in prevention of Postpartum hemorrhage after cesarean section

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 300 participants
Study completion date: December 2015
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
January 15, 2014
Actual (reported)
First Posted
January 24, 2014
Actual (reported)
Study Start
June 2014
Actual (reported)
Primary Completion
December 2015
Actual (reported)
Study Completion
December 2015
Actual (reported)

Last Updated: June 24, 2021
Status Verified: June 2021
Last Update Submitted: June 23, 2021

Conditions

Blood Loss Postpartum Hemorrhage

Keywords

Carbetocinsyntometrinepostpartum hemorrhagecesarean section

Outcome Measures

Primary Outcomes (1)

prevention of post partum hemorrhage after CS
Number of participants experienced postpartum hemorrhage
24 hours

Secondary Outcomes (1)

side effects of drugs used
24 hours

Study Arms (2)

carbetocin

ACTIVE COMPARATOR

single 100 μg IV dose of carbetocin (150 women) after fetal extraction and before placental removal.

Drug: carbetocin

Syntometrine

ACTIVE COMPARATOR

Intravenous combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal.

Drug: Syntometrine

Interventions

carbetocinDrug

Oxycontin analogue

Also known as: Pabal

carbetocin

SyntometrineDrug

Uterotonins

Also known as: Oxytocin methergine combination

Syntometrine

Eligibility Criteria

Age18 Years - 39 Years

Sexfemale

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

All participants are at 37 - 40 weeks of gestational age
Noncomplicated pregnancy.

You may not qualify if:

Sponsors & Collaborators

Cairo University
Otherlead

Study Sites (1)

Ahmed Maged

Cairo, 12151, Egypt

MeSH Terms

Conditions

Postpartum HemorrhageHemorrhage

Interventions

carbetocinsyntometrine

Condition Hierarchy (Ancestors)

Obstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesPuerperal DisordersUterine HemorrhagePathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Ahmed Maged, MD
Ass prof kasr aini medical school
PRINCIPAL INVESTIGATOR

Enrollment

300 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 4
Allocation: RANDOMIZED
Masking: DOUBLE
Who Masked: PARTICIPANT, INVESTIGATOR
Purpose: PREVENTION
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Assistant professor

Study Record Dates

First Submitted

January 15, 2014

First Posted

January 24, 2014

Study Start

June 2014

Actual (reported)

NCT03556852

CARBETOCIN VERSUS RECTAL MISOPROSTOL FOR MANAGEMENT OF THIRD STAGE OF LABOR IN WOMEN AT LOW RISK OF POSTPARTUM HEMORRHAGE

Phase 4Completed

NCT01630187

Comparison of Two Doses of Carbetocin for Prevention of Uterine Atony, During Elective Cesarean Section

Phase 4Completed

NCT04300452

Carbetocin Versus Ergometrin in the Prevention of Postpartum Hemorrhage

Phase 4Unknown

NCT01579201

ED90 Determination of Carbetocin for the Prevention of Uterine Atony in Women Undergoing an Elective Cesarean Delivery

Phase 4Unknown

NCT03651882

Oxytocin i.m./i.v. Versus Carbetocin i.v. in Elective Cesarean Sections

Phase 4Completed

NCT02226588

Comparison of Primary and Secondary Prevention of Postpartum Hemorrhage at the Community Level in Egypt

Phase 4Completed

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Participants with placenta previa
Patients with coagulopathy
preeclamptic women
known sensitivity to oxytocin or methergine were excluded

Contact the study team to confirm eligibility.

Primary Completion

December 2015

Actual (reported)

Study Completion

December 2015

Actual (reported)

Last Updated

June 24, 2021

Record last verified: 2021-06

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT02044549
Data provider: ClinicalTrials.gov
Source updated: 2021-06-24
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:31:06 UTC

Locations

EG(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (2)

carbetocin

Syntometrine

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations